Company intelligence / Profile preview

Sphebio Co., Ltd.

Pohang-si, Gyeongsangbuk-do, South Koreaen.sphebio.com ↗

Ownership: Private
Development stage: Preclinical

Overview

Sphebio is developing a proprietary 3D cell-printing platform for the fabrication of artificial organs/tissues, with demonstrated preclinical results in periodontal ligament regeneration. Animal studies have shown increased connective tissue formation using their hybrid artificial organ approach. The company has also entered into partnerships to develop next-generation therapies for hair loss using dermal papilla spheroids[6][2].

Therapeutic areas: OtherDermatology
Modalities: Cell therapy3D bioprinting/bioprinted tissues
Industry: Biotech

Partnerships

EpiBiotech – MOU signed to co-develop dermal papilla spheroid production technologies targeting next-generation hair loss treatments[6].

Beyond the preview

Go deeper on Sphebio Co., Ltd..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Sphebio Co., Ltd..

Explore the full profile